Skip to main content
. 2019 Aug 2;7(4):10.1128/microbiolspec.gpp3-0045-2018. doi: 10.1128/microbiolspec.gpp3-0045-2018

FIGURE 13.

FIGURE 13

Reactivity of serum samples originating from the United States with human cardiac myosin peptides from the S2 and LMM regions in the enzyme-linked immunosorbent assay (1:100 serum dilution). (A) Mean reactivity of normal serum samples from control donors with no evidence of streptococcal infection or heart disease on the U.S. mainland against S2 and LMM peptides. These samples rarely reacted with any S2 or LMM peptide at an optical density of 0.2. (B) Mean reactivity of serum samples from patients with streptococcal pharyngitis in the United States against S2 and LMM peptides. These samples rarely reacted with any S2 or LMM peptide at an optical density of 0.2. (C) Serum immunoglobulin G from patients with rheumatic carditis in the United States. Serum samples from patients with rheumatic carditis from the United States reacted predominantly with peptides S2-1, S2-4, S2-5, S2-8, S2-9, S2-17, and S2-30, compared with the reactivity of serum samples from patients with pharyngitis in the United States against those same peptides (B). (C) Unadjusted Mann-Whitney P values for the comparison between carditis and pharyngitis on the United States mainland. The comparison for S2-4 is statistically significant on the basis of a two-sided alpha level adjusted to preserve the false-discovery rate at 5%. (Taken from Ellis et al. [24] with permission from the Journal of Infectious Diseases).